Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Factors influencing the incubation of an infectious form of Creutzfeldt-Jakob disease.

Peckeu L, Brandel JP, Welaratne A, Amar E, Costagliola D, Haïk S.

Clin Infect Dis. 2019 Jul 28. pii: ciz692. doi: 10.1093/cid/ciz692. [Epub ahead of print]

PMID:
31351441
2.

Amplification techniques and diagnosis of prion diseases.

Brandel JP, Culeux A, Grznarova K, Levavasseur E, Lamy P, Privat N, Welaratne A, Denouel A, Laplanche JL, Haik S.

Rev Neurol (Paris). 2019 Sep - Oct;175(7-8):458-463. doi: 10.1016/j.neurol.2019.06.002. Epub 2019 Jul 8. Review.

PMID:
31296398
3.

Susceptibility to Creutzfeldt-Jakob disease after human growth hormone treatment in France.

Peckeu L, Brandel JP, Welaratne A, Costagliola D, Haïk S.

Neurology. 2018 Aug 21;91(8):e724-e731. doi: 10.1212/WNL.0000000000006028. Epub 2018 Jul 25.

PMID:
30045957
4.

Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease.

Bougard D, Brandel JP, Bélondrade M, Béringue V, Segarra C, Fleury H, Laplanche JL, Mayran C, Nicot S, Green A, Welaratne A, Narbey D, Fournier-Wirth C, Knight R, Will R, Tiberghien P, Haïk S, Coste J.

Sci Transl Med. 2016 Dec 21;8(370):370ra182. doi: 10.1126/scitranslmed.aag1257.

PMID:
28003547
5.

Optimal target localization for subthalamic stimulation in patients with Parkinson disease.

Welter ML, Schüpbach M, Czernecki V, Karachi C, Fernandez-Vidal S, Golmard JL, Serra G, Navarro S, Welaratne A, Hartmann A, Mesnage V, Pineau F, Cornu P, Pidoux B, Worbe Y, Zikos P, Grabli D, Galanaud D, Bonnet AM, Belaid H, Dormont D, Vidailhet M, Mallet L, Houeto JL, Bardinet E, Yelnik J, Agid Y.

Neurology. 2014 Apr 15;82(15):1352-61. doi: 10.1212/WNL.0000000000000315. Epub 2014 Mar 19.

6.

Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial.

Haïk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, Azimi S, Pietrini V, Fabreguettes JR, Imperiale D, Cesaro P, Buffa C, Aucan C, Lucca U, Peckeu L, Suardi S, Tranchant C, Zerr I, Houillier C, Redaelli V, Vespignani H, Campanella A, Sellal F, Krasnianski A, Seilhean D, Heinemann U, Sedel F, Canovi M, Gobbi M, Di Fede G, Laplanche JL, Pocchiari M, Salmona M, Forloni G, Brandel JP, Tagliavini F.

Lancet Neurol. 2014 Feb;13(2):150-8. doi: 10.1016/S1474-4422(13)70307-7. Epub 2014 Jan 8.

PMID:
24411709
7.

Can mortality data provide reliable indicators for Creutzfeldt-Jakob disease surveillance? A study in France from 2000 to 2008.

Brandel JP, Welaratne A, Salomon D, Capek I, Vaillant V, Aouba A, Haïk S, Alpérovitch A.

Neuroepidemiology. 2011;37(3-4):188-92. doi: 10.1159/000332764. Epub 2011 Nov 2. Erratum in: Neuroepidemiology. 2012;38(3):193. Aouaba, Albertine [corrected to Aouba, Albertine].

PMID:
22057088
8.

14-3-3 protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeldt-Jakob disease patients.

Brandel JP, Peoc'h K, Beaudry P, Welaratne A, Bottos C, Agid Y, Laplanche JL.

Ann Neurol. 2001 Feb;49(2):257-60.

PMID:
11220747

Supplemental Content

Loading ...
Support Center